In a study evaluating the performance of the software Cellda® Prostate, 640 digital images of prostate biopsies from 364 patients were evaluated both by pathologists and Cellda® Prostate. The results show high conformity with a sensitivity of 92% (significantly higher than the limit of 80% for the study to be approved) and specificity of 81%.
“This is an important milestone, and we are very pleased with the results. It has been a great team effort to achieve this”, Susanne Bredenberg, CEO of Cellda, says.
In addition, when studying the results of images with same diagnosis of all pathologists (569 of the in total 640 images) the conformity was even higher with a sensitivity of 96% and specificity of 84%. These results give a strong indication that Cellda Prostate will function as a great support to pathologists when evaluating complex images of prostate biopsies.
“To our knowledge, this is the first software analysing digital images of prostate biopsies stained using immunohistochemistry protocols. This study indicates the potential of Cellda’s products increasing the quality of cancer diagnostics and improved patient treatments”, Susanne Bredenberg concludes.